- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha | ||
| 30.04. | NewcelX Ltd.: NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | 348 | GlobeNewswire (Europe) | NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term... ► Artikel lesen | |
| 30.04. | EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug | 3 | Benzinga.com | ||
| 30.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.04. | NewcelX informiert über Fortschritte bei Diabetes-Therapie-Kooperation | 2 | Investing.com Deutsch | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 20.04. | NewcelX updates presentation on diabetes therapy collaboration | 3 | Investing.com | ||
| 20.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | NewcelX prices $1.35M equity financing | 1 | Seeking Alpha | ||
| 01.04. | NewcelX sichert sich 1,35 Mio. US-Dollar durch Privatplatzierung mit 30 % Aufschlag | 16 | Investing.com Deutsch | ||
| 01.04. | NewcelX raises $1.35M in private placement at 30% premium | 2 | Investing.com | ||
| 01.04. | NewcelX Ltd.: NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | 3 | GlobeNewswire (USA) | ||
| 10.03. | NewcelX and Eledon partner for NCEL-101 programme | 4 | Pharmaceutical Technology | ||
| 09.03. | NewcelX Enters Strategic Collaboration With Eledon Pharma | - | RTTNews | ||
| 09.03. | NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes | 1 | Contract Pharma | ||
| 09.03. | NewcelX Ltd.: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | 918 | PR Newswire | Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq:... ► Artikel lesen | |
| 09.03. | Typ-1-Diabetes: NewcelX und Eledon starten Forschungskooperation | 1 | Investing.com Deutsch | ||
| 09.03. | NewcelX partners with Eledon on type 1 diabetes therapy | 2 | Investing.com | ||
| 09.03. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,080 | +3,67 % | Shortseller-Positionen aktuell: u.a. Evotec, FMC, Gerresheimer, Hypoport, Nagarro, Nordex, Suss MicroTec | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 40,770 | +0,22 % | Moderna Flu Shot Heads To FDA Advisory Panel | ||
| VALNEVA | 2,517 | +0,80 % | Valneva Aktie: Prognose kassiert - die Börse schaut woanders hin | Valneva hat das erste Quartal 2026 mit einem deutlichen Umsatzrückgang abgeschlossen und die Jahresprognose gesenkt. Der Aktienkurs reagierte nicht entscheidend, denn der Markt richtet seinen Blick... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,340 | 0,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June | ||
| INTELLIA THERAPEUTICS | 10,640 | -0,19 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| ARBUTUS BIOPHARMA | 3,750 | -1,83 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| XOMA ROYALTY | 35,600 | -1,11 % | Ligand Pharmaceuticals und XOMA Royalty passen Fusionsvereinbarung an | ||
| CELLECTAR BIOSCIENCES | 3,170 | 0,00 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement | OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct... ► Artikel lesen | |
| NOVOCURE | 14,710 | -4,54 % | Novocure Reports First Quarter 2026 Financial Results | Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio
Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic... ► Artikel lesen | |
| PHARMING | 1,130 | -0,04 % | Pharming Group N.V.: Pharming Group reports first quarter 2026 financial results; on track for Joenja U.S. pediatric label expansion and launches in Japan and Europe in 2026 | First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025RUCONEST revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly... ► Artikel lesen | |
| TRAWS PHARMA | 1,500 | +0,67 % | Traws Pharma, Inc.: Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results | Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza... ► Artikel lesen | |
| CYTOKINETICS | 67,76 | +0,89 % | Cytokinetics, Incorporated: Cytokinetics to Hold Annual Meeting of Stockholders |
NEWCELX LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,62 % bei einem Aktienkurs von 3,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.